Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1517-1522

  Hung, Ming Szu ^a,b,c,d   Xu, Zhidong ^a   Chen, Yu ^e   Smith, Emmanuel ^e   Mao, Jian Hua ^f   Hsieh, David ^a   Lin, Yu Ching ^b,c,d   Yang, Cheng Ta ^b,c   Jablons, David M ^a   You, Liang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Casein kinase II; Hematein; Lung cancer; Wnt; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CASEIN KINASE II; CASEIN KINASE II ALPHA; HEMATEIN; PROTEIN KINASE B; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; IC 50; LUNG CANCER; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASEIN KINASE II; ENZYME INHIBITORS; FEMALE; HEMATOXYLIN; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; T CELL TRANSCRIPTION FACTOR 1; TUMOR CELLS, CULTURED; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885037892     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2087     Document Type: Article

References (27)

1. Meggio F and Pinna LA: One-thousand-and-one substrates of protein kinase CK2? FASEB J 17: 349-368, 2003.
2. Pinna LA: The raison d'etre of constitutively active protein kinases: the lesson of CK2. Acc Chem Res 36: 378-384, 2003.
3. Tawfic S, Yu S, Wang H, Faust R, Davis A and Ahmed K: Protein kinase CK2 signal in neoplasia. Histol Histopathol 16: 573-582, 2001.
4. Seldin DC and Leder P: Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 267: 894-897, 1995.
5. Landesman-Bollag E, Song DH, Romieu-Mourez R, et al: Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem 227: 153-165, 2001.
6. Kim JS, Eom JI, Cheong JW, et al: Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 13: 1019-1028, 2007.
7. Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL and Cochet C: Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 43: 928-934, 2007.
8. O-charoenrat P, Rusch V, Talbot SG, et al: Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 10: 5792-5803, 2004.
9. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL and Ahmed K: Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med 1: 659-666, 1995.
10. Stalter G, Siemer S, Becht E, Ziegler M, Remberger K and Issinger OG: Asymmetric expression of protein kinase CK2 sub- units in human kidney tumors. Biochem Biophys Res Commun 202: 141-147, 1994.
11. Ruzzene M, Penzo D and Pinna LA: Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364: 41-47, 2002.
12. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z and Pinna LA: 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321: 1040-1044, 2004.
13. Sarno S, De Moliner E, Ruzzene M, et al: Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem J 374: 639-646, 2003.
14. Siddiqui-Jain A, Drygin D, Streiner N, et al: CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70: 10288-10298, 2010.
15. Hung MS, Xu Z, Lin YC, et al: Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library. BMC Cancer 9: 135, 2009.
16. Oh SR, Kim DS, Lee IS, Jung KY, Lee JJ and Lee HK: Anticomplementary activity of constituents from the heartwood of Caesalpinia sappan. Planta Med 64: 456-458, 1998.
17. Bettinger C and Zimmermann HW: New investigations on hematoxylin, hematein, and hematein-aluminium complexes. II. Hematein-aluminium complexes and hemalum staining. Histochemistry 96: 215-228, 1991.
18. Lorber DM and Shoichet BK: Hierarchical docking of databases of multiple ligand conformations. Curr Top Med Chem 5: 739-749, 2005.
19. Raaf J, Brunstein E, Issinger OG and Niefind K: The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. Chem Biol 15: 111-117, 2008.
20. Meng EC, Shoichet BK and Kuntz ID: Automated docking with grid-based energy evaluation. J Computat Chem 13: 505-524, 1992.
21. Raaf J, Issinger OG and Niefind K: Insights from soft X-rays: the chlorine and sulfur sub-structures of a CK2alpha/DRB complex. Mol Cell Biochem 316: 15-23, 2008.
22. Di Maira G, Salvi M, Arrigoni G, et al: Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12: 668-677, 2005.
23. Duncan JS and Litchfield DW: Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 1784: 33-47, 2008.
24. Yde CW, Frogne T, Lykkesfeldt AE, Fichtner I, Issinger OG and Stenvang J: Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett 256: 229-237, 2007.
25. Tapia JC, Torres VA, Rodriguez DA, Leyton L and Quest AF: Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci USA 103: 15079-15084, 2006.
26. Ponce DP, Yefi R, Cabello P, et al: CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Mol Cell Biochem 356: 127-132, 2011.
27. Moucadel V, Prudent R, Sautel CF, et al: Antitumoral activity of allosteric inhibitors of protein kinase CK2. Oncotarget 2: 997-1010, 2011.